Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod PH20 SC in CIDP Patients Transitioning from IVIg
NCT06637072Phase 4Completed
- Sponsor
- argenx
- Start
- Dec 2024
- Primary completion
- Feb 2026
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
A Phase 4 trial of efgartigimod alfa in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by argenx. Started Dec 2024; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT06637072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06637072.